Insider · CIK 0001243514
J Matthew Singleton
Files at VKTX (Viking Therapeutics, Inc.). First filing Oct 25, 2024, latest Oct 25, 2024.
J Matthew Singleton files SEC Form 4 as director at VKTX (Viking Therapeutics, Inc.). Since Oct 25, 2024, J Matthew Singleton has reported 0 open-market buys worth $0 and 1 open-market sell worth $1.3M, the latest filed on Oct 25, 2024.
A track record needs three past buys with six months of prices behind them; J Matthew Singleton has 0, so none is measured yet.
The newest scored trade: sold $1.3M of VKTX on Oct 25, 2024, filed Oct 25, 2024, scored 40 (moderate), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VKTX: Viking Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Viking Therapeutics, Inc. | $1.3M 16,000 shares | -63% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | 16,000 0.01% of outstanding | $1.3M | Oct 25, 2024 | $3.3M |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +3,150 | $0.00 | $0 | 12,650 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Jan 5, 2026 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +16,000 | $4.48 | $72k | 25,500 | Oct 25, 2024 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -16,000 | $79.50 | $1.3M | 9,500 | Oct 25, 2024 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,000 | $0.00 | $0 | 0 | Oct 25, 2024 |
Questions about J Matthew Singleton
Answered from the filings on this page, as of the latest one.
Is J Matthew Singleton buying or selling?
Not in the last 12 months. J Matthew Singleton's latest open-market trade on SEC Form 4 was sold $1.3M of VKTX on Oct 25, 2024.
How did J Matthew Singleton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and J Matthew Singleton has 0.
Where does J Matthew Singleton file Form 4?
J Matthew Singleton has filed Form 4 at VKTX (Viking Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.